Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAg trends

Saturday, June 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the positive outcomes of extended treatment with ALG-000184 in HBeAg+ chronic hepatitis B subjects. The treatment is associated with significant reductions in viral markers and favorable trends in anti-HBeAg. The results suggest a potential benefit of combining ALG-000184 with Entecavir.
Price reaction · baseline $14.75 (2024-05-31 close) · 2 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Extended treatment shows promise in reducing viral markers.
  • Favorable trends in anti-HBeAg observed.
  • Potential benefits of ALG-000184 with or without Entecavir.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a capsid assembly modulator being studied for chronic HBV treatment.

What were the results of the study?

The study found reductions in viral markers and favorable trends in anti-HBeAg.

How does ALG-000184 compare to Entecavir?

The study explores ALG-000184's effects both with and without Entecavir.

Who are the subjects in the study?

The subjects are HBeAg+ individuals with chronic hepatitis B.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 chronic HBV viral markers anti-HBeAg Entecavir
Last updated: Jun 1, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →